ZS Pharma to price IPO of 5 million shares between $15.00 and $17.00

J.P. Morgan and Credit Suisse are joint bookrunning managers

By Devika Patel

Knoxville, Tenn., June 6 – ZS Pharma, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe option of 750,000 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The deal was announced on May 15.

The shares will be sold at a price expected to fall between $15.00 and $17.00 per share.

J.P. Morgan and Credit Suisse are the joint bookrunning managers. BMO Capital Markets and William Blair are the co-managers.

Proceeds will be used to advance the company’s clinical program, to seek approvals to market ZS-9 for the treatment of hyperkalemia, to scale up manufacturing facilities for ZS-9, to build a specialty sales force infrastructure and complete pre-commercialization marketing activities for ZS-9, for working capital and other general corporate purposes.

The biopharmaceutical company is based in Coppell, Texas. The company intends to list its common stock on the Nasdaq under the symbol “ZSPH.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.